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Gastrointestinal tract (GIT) involvement is the most common internal organ 
manifestation and is present in up to 90% of patients with systemic sclerosis (SSc). 
Clinical manifestations can differ according to the part of the GIT affected, disease 
course and symptoms. A majority of the symptoms are caused by GIT dysmotil-
ity. Up to 8% of SSc patients develop several GIT symptoms, which increase the 
mortality. Although GIT involvement is rarely the direct cause of death, it can lead 
to several comorbidities including malnutrition and negative alterations of body 
composition. These factors have a negative impact on quality of life and increase the 
mortality. To date, the treatment is rather symptomatic. The pathogenesis of GIT 
involvement in SSc still remains to be clarified to improve the treatment approaches 
including intravenous immunoglobulins and microRNA interventions.
Keywords: gastrointestinal tract, systemic sclerosis, malnutrition, body composition, 
diagnosis, management
1. Introduction
Systemic sclerosis (SSc), characterised by autoimmune inflammation, vascu-
lopathy and fibrotic tissue deposition as the main pathophysiological features, can 
affect any organ system. In fact, the aetiology and pathophysiology of SSc are still 
not completely elucidated [1]. Gastrointestinal tract (GIT) is one of the most com-
monly involved organ systems in SSc.
Up to 90% of SSc patients are affected by some degree of GIT fibrosis, with no 
difference in frequency in limited cutaneous systemic sclerosis (lcSSc) and diffuse 
cutaneous systemic sclerosis (dcSSc) subsets. However, more severe involvement 
and increased mortality occur rather in dcSSc than lcSSc [2, 3]. Dysmotility is the 
cardinal pathological abnormality, which can affect any part of GIT and contributes 
to the majority of symptoms [4], which are mostly non-specific and overlapping for 
a particular anatomical site. GIT involvement varies in extent, severity and course 
and can manifest even in the absence of cutaneous disease [5].
New Insights into Systemic Sclerosis
2
The pathophysiology of GIT involvement in general corresponds to the skin 
and other organ involvement in SSc, with the main characteristic pathologic 
features: vascular abnormalities, immune cell infiltration in tissue, autoantibodies 
and typical extensive deposition of collagen fibres. This process leads to specific 
early myenteric neural dysfunction caused by autoantibodies and collagen deposi-
tion, vasculopathy in myointimal layer mainly in capillaries preceding the muscle 
changes, smooth muscle cell infiltration with mononuclear cells with consequent 
atrophy and fibrosis of enteric connective tissue [1, 6]. Regarding the aetiology, 
genetic component is supposed to play a significant role in GIT involvement. In 
the Canadian population study, in which SSc patents were classified according 
to the ethnicity, population of white patients had less severe GIT involvement 
compared to North American native population (including American Indians and 
others), suggesting a predisposition for severity and progression of the disease [7]. 
Another study identified some haplotypes in an American native population 
(Choctaw Indians) strongly associated with SSc and more severe progression of 
this disease (HLA-DRB1*1602, DQB1*0301 and DQA1*0501) [8]. Some studies 
have also reported high prevalence of Helicobacter infection in SSc patients, sup-
porting the hypothesis of infectious aetiology [9]. Smoking has been identified as 
the only environmental factor associated with increased severity of GIT symptoms 
in SSc [10].
GIT involvement significantly impacts quality of life and contributes to 
depression, sleep disturbance and pain [11–13]. It also negatively influences the 
prognosis with up to 12% of mortality due to fibrosis of GIT and accompanying 
malnutrition [1]. Up to 8% of SSc patients can develop severe GIT symptoms, which 
lead to increased mortality with only 15% survival at 9 years [5].
2. Pathophysiology
The pathophysiology of GIT involvement in SSc is a complex process. 
Unfortunately, it is still poorly understood due to many reasons: heterogeneity of 
clinical manifestations, the lack of appropriate animal models and the paucity of 
studies examining the pathophysiology. The key pathogenic mechanisms of GIT 
involvement, similarly to SSc in general, include fibro-proliferative vasculopathy, 
immune dysfunction with the participation of various components of immune 
system and fibrosis [14].
Endothelial injury as the crucial event in SSc results in increased production 
of reactive oxygen species (ROS) and release of chemokines and growth factors. 
Recruited immune cells (B- and T-cells and pro-fibrotic macrophages) contribute 
to further release of ROS, cytokines and pro-fibrotic mediators [15]. These mecha-
nisms lead to reduced blood flow in mucosa, endothelial cell apoptosis, perivascular 
infiltrates and thickening of the basement membrane [16–18].
The initial step in pathophysiology of GIT dysmotility is neuropathy, followed 
by myopathy and later by progress to fibrosis [19]. Specific autoantibodies isolated 
from serum of SSc patients (SSc-IgGs) were described to cause significant smooth 
muscle dysfunction [20]. The mechanism lies in inhibition of acetylcholine binding 
on the M3 receptors (M3-Rs) [21, 22]. The action of SSc-IgGs seems to be dependent 
on the disease stage: in early SSc there is higher affinity of SSc-IgGs to the M3-Rs of 
myenteric neurons, which represents the neuropathic damage. During the course of 
the disease, the affinity increases to both smooth muscle cells and myenteric neu-
rons, representing the myopathic phase. This temporal increase of SSc-IgGs affinity 
could elucidate the progressive character of GIT involvement [14, 19, 23].  
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Presence and action of M3-R autoantibodies can explain the impaired GIT function 
explored by manometry before the occurrence of histological changes [14].
Neutralisation of M3-R antibodies by human intravenous immunoglobulins 
(IVIGs) and its antigen-binding fragment F(ab)2 might reverse the intestinal 
dysfunction and is considered as a potential therapy [19]. The ultimate smooth 
muscle cell atrophy and tissue fibrosis lead to the loss of GIT contractile function 
and disability to respond to any external stimuli; thus any treatment of dysmotility 
is futile [14].
Alterations in cell-mediated immunity have a significant role in SSc GIT involve-
ment [24, 25]. Interleukin (IL)-4 stimulates type 2 helper (Th2) polarisation of 
CD4+ T-cells, which is predominant in SSc. Th2 cells further upregulate humoral 
immunity [15, 26]. CD4+ T-cells in immune cell infiltrates in gastric biopsy speci-
mens with typically increased CD4+/CD8+ T-cell ratio can be responsible for patho-
genic autoantibody production and fibrosis of GIT [14, 27]. Generalised fibrosis 
with increased deposition of collagens I and III in most layers (muscularis mucosae, 
submucosa and muscularis propria) was described in gastric wall biopsies, together 
with strong expression of fibrogenic cytokines (transforming growth factor-β and 
connective tissue growth factor) and α-smooth muscle actin [28]. Other factors 
contributing to fibrosis are reduction of matrix metalloproteinase-1 expression and 
damage and reduction of telocytes—specific stromal cells essential for extracellular 
matrix scaffolding [29, 30]. Moreover, consequent increased stiffness of GIT wall is 
an additional potential stimulus for further fibrosis [31].
In addition, differentially expressed microRNAs (miRNAs) targeting both 
inflammation and fibrotic pathways have a probable role in SSc pathogenesis [32, 33]. 
Depletion of the miR-29 family, which targets collagen gene expression and regulates 
fibrosis, probably leads to increased collagen deposition in tissues [34].
3. Clinical manifestations
As mentioned, any part of GIT can be affected, so the clinical manifestations 
vary according to the involved organ. Large proportion of patients are asymptom-
atic, or symptoms may be unspecific and overlapping [1]. Fibrosis and dysfunction 
of GIT lead to many complications, such as gastro-oesophageal reflux disease 
(GERD) with complications (oesophageal strictures, Barrett’s oesophagus), dila-
tion and non-compliance of the stomach (gastroparesis), small intestinal bacterial 
overgrowth (SIBO), colonic dilation and dysfunction of internal anal sphincter. 
The vasculopathic manifestations are gastric antral vascular ectasia (GAVE), small 
intestine vascular ectasia and diverticula in the oesophagus, small intestine and 
colon, resulting in malabsorption and faecal incontinence [14]. Clinical features are 
divided according to individual organ involvement.
3.1 Oral cavity and pharynx
There are numerous SSc-related alterations of the oral cavity [35]. Pathognomic 
fibrosis results in characteristically reduced oral aperture (microstomia), thicken-
ing of the sublingual fraenulum and widening of periodontal ligaments [36]. In 
addition, secondary Sjögren’s syndrome, reported in about one fifth of SSc patients, 
can lead to tooth loss along with above-mentioned pathologies. All these factors 
complicate dental hygiene and food intake and contribute to malnutrition [37]. 
Up to 20% of SSc patients can develop mandibular resorption predisposing to 
pathological fractures, osteomyelitis and trigeminal neuralgia [38]. Oropharyngeal 
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dysphagia manifests in 25% of SSc patients and is caused both by dysmotility and 
GER as a reflex mechanism [39]. Apart from malnutrition, dysphagia is also a risk 
factor for aspiration pneumonia [40]. With regard to malignancy, risk of tongue 
cancer (squamous cell carcinoma) has been reported in dcSSc 25-fold higher 
compared to general population [41].
3.2 Oesophagus
Oesophageal dysfunction appears to be the most common GIT manifestation 
in SSc affecting up to 90% SSc patients with higher prevalence and tendency to 
deteriorate over time in dcSSc compared to lcSSc [42, 43]. Up to 30% of SSc patients 
may suffer from asymptomatic oesophageal involvement [44]. The main feature 
of oesophageal involvement is dysphagia due to smooth muscle cell atrophy and 
destruction of neuronal complexes. Drug-induced dysphagia and Candida oesopha-
gitis caused by immunosuppressive treatment should be also taken into account. 
Reduced lower oesophageal sphincter (LES) tone along with dilation of the lumen, 
peristalsis disorder and gastroparesis is the main predisposing factor for GERD and 
consequent complications. Among typical symptoms asthma should not be omitted 
when taking patient’s history [14, 42].
Long-standing GERD results in development of distal reflux oesophagitis and 
eventually progresses to peptic strictures and Barrett’s oesophagus (BE) formation. 
The prevalence of BE is reported to be 12.7% in SSc patients treated with proton-
pump inhibitors (PPIs) [45]. Approximately 20% of these patients develop dyspla-
sia and are at higher risk of adenocarcinoma compared to SSc patients with BE and 
without dysplasia. However, this risk seems not to be increased in SSc compared to 
general population with GERD [45, 46].
The recent high-resolution manometry study reported positive correlation of 
severe oesophageal dysmotility with the duration of SSc and presence of interstitial 
lung disease (ILD) [47]. GERD can contribute to the emergence of ILD and worsen 
the ILD in SSc by microaspiration of gastric content; therefore, early diagnosis and 
administration of high-dose PPI therapy are needed [48, 49].
3.3 Stomach
Gastric involvement leads mainly to gastroparesis and GAVE [50]. Gastroparesis 
manifests clinically by early satiety, nausea and vomiting, epigastric discomfort 
and bloating and may progress to complete food intolerance [51, 52]. GAVE, 
also called “watermelon stomach”, is considered a macroscopic manifestation of 
SSc vasculopathy, corresponds with skin telangiectasias and is associated with 
Raynaud’s phenomenon [53, 54]. The prevalence of GAVE in SSc ranges from 6 
to 22% [53–56]. It usually occurs within the first few years from the onset of the 
disease. Nevertheless, it can also be the first SSc manifestation in the absence of 
cutaneous involvement, clinically expressed as anaemia of combined aetiology: 
iron deficiency (sideropenia) and chronic bleeding (occult bleeding, melena or 
haematemesis) [56]. The presence of GAVE correlated negatively with the positiv-
ity of anti-topoisomerase I antibodies, but, in one study, was not associated with 
anti-RNA polymerase III autoantibodies (anti-RNAP3) [54]. However, on contrary, 
an association was confirmed in the recent study of EUSTAR population, where 
48% of patients with GAVE had anti-RNAP3 positivity compared to 16% of SSc 
patients without GAVE. Of note, the autoantibody profile was not available for 
the whole cohort of SSc patients included [57]. A more recent study of EUSTAR 
population including almost 5000 SSc patients assessing the association of anti-
RNAP3 autoantibodies with clinical features and risk of malignancies reported, 
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among other results, a negative association of anti-RNAP3 with GERD and a 
positive association of anti-RNAP3 with GAVE (more than eight times increased 
risk of GAVE in anti-RNAP3-positive patients than in anti-RNAP3-negative SSc 
patients) [58]. The association with specific antibodies and its potential clinical use 
is a quest for further studies.
3.4 Small intestine
The small intestine belongs to the most commonly affected organ of GIT 
involvement in SSc, after the oesophagus and anorectum. Decreased motility 
results in typical complications, which participate in malabsorption and malnutri-
tion: local small bowel dilation, intestinal pseudo-obstruction and SIBO, develop-
ment of pneumatosis cystoides intestinalis (PCI) and jejunal diverticula [59]. 
The range of symptoms is wide, from dyspeptic symptoms to systemic symptoms 
resulting from malabsorption [14].
Predisposing factors for pseudo-obstruction, either acute or chronic, are both 
SSc related—dilation, atony and delayed transit—and treatment related, espe-
cially the use of opiates [51, 60]. The stasis due to dysmotility of intestinal content 
predisposes to SIBO that was detected in up to 40–50% of SSc patients [51, 61]. This 
can, along with the failure of recurrent antibiotics therapy, cause the vulnerability 
to severe malabsorption [62].
PCI is a rare complication of SSc characterised by multiple gas-filled cysts 
in submucosa or subserosa [63] as an incidental radiographic (RDG) finding. 
Contributing factors involve dysmotility with consequent SIBO, ischemic dam-
age and muscular atrophy [64]. Rarely, the rupture can cause benign spontaneous 
pneumoperitoneum or more severe complications as bowel ischaemia, perforation 
and peritonitis [63]. The treatment of benign pneumoperitoneum consists of 
conservative approach (oxygen, antibiotics and bowel rest) or surgery intervention 
in more severe cases [14].
3.5 Large intestine
Colonic involvement, including hypomotility, telangiectasia and diverticula, 
affects up to 50% of SSc patients and is often asymptomatic or can typically 
manifest by chronic constipation and abdominal distension [1]. Dysmotility and 
the resulting constipation can in extreme cases lead to faecal impaction or perfora-
tion requiring surgery. The colon can be dilated with the loss of haustration [14]. 
SSc patients can also suffer from diarrhoea and severe malabsorption caused by 
SIBO [65].
Colon and anorectal involvement can manifest by rectal prolapse and diver-
ticula typically described as “wide mouth”, which are mostly asymptomatic and 
not complicated by diverticulitis. Anorectal involvement is regarded as the second 
most common with a prevalence of 50–70% [14]. Symptoms include incontinence, 
tenesmus and painful defaecation. Faecal incontinence, present in 40% SSc 
patients, is generally attributable to several factors: diarrhoea, internal and external 
anal sphincter dysfunction, reduced rectal compliance and capacity with impaired 
recto-anal inhibitory reflex, rectal prolapse and also constipation with overflow 
[66, 67]. Dysfunction of smooth muscles in internal anal sphincter (neuropathic 
or myopathic) is supposed to be the initial cause of faecal incontinence [68]. The 
main cause of sphincter involvement seems to be the vasculopathy and resulting 
tissue atrophy described in endo-anal ultrasound imaging as a hyperechoic thinned 
sphincter. On the other hand, thick hypoechoic sphincter due to tissue fibrosis is 
found in some cases [69].
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3.6 Liver and pancreas
Involvement of the liver is less frequent compared to GIT organs mentioned 
above. Nodular regenerative hyperplasia (NRH), benign liver involvement in SSc, 
can precede primary biliary cirrhosis (PBC) and can progress to non-cirrhotic 
portal hypertension [70, 71]. The pathogenesis lies in obliterative changes in portal 
veins and corresponds with the microvascular damage in SSc. Although NRH is 
mostly asymptomatic, it can develop into portal hypertension [72].
Primary biliary cirrhosis is the most common liver disorder associated with SSc 
with a prevalence of about 2%, higher in lcSSc [73]. It can precede the diagnosis 
of SSc, for example, as a Reynolds syndrome comprising PBC with Raynaud’s 
phenomenon [74]. PBC is associated with anti-centromere antibody positivity [73]. 
Nevertheless, PBC screening antibodies (anti-mitochondrial, anti-gp21, anti-
sp100) are detectable also in 20% of SSc patients with no liver disease [75]. The 
rate of progression of SSc-related PBC to end-stage liver disease and transplanta-
tion is lower compared to non-SSc PBC, but the reason is still unknown [76]. PBC 
contributes via cholestasis and decreased bile acid secretion to malabsorption and 
malnutrition [1].
Other rare liver infections in SSc include autoimmune hepatitis, idiopathic 
portal hypertension and primary sclerosing cholangitis [77, 78]. Specific anti-liver 
kidney microsomal (anti-LKM) or anti-smooth muscle (anti-SMA) antibodies 
detected in SSc without liver involvement are attributable to the autoimmune 
character of SSc [79].
The involvement of the pancreas seems to be rare and the symptoms can overlap 
with SIBO. The exocrine pancreatic insufficiency can take part in malabsorption [80]. 
Case reports describe occlusion of medium-sized pancreatic arteries in SSc resulting 
in haemorrhagic pancreatitis and fatal pancreatic infarction [81].
4. Malnutrition
Prevalence of malnutrition in SSc patients is estimated to be 15–58% [51, 82, 83]. 
Mortality is significantly increased in underfed SSc patients compared to patients 
with adequate nutritional intakes, whereas about 4% deaths are attributable to 
consequences of malnutrition [14, 83]. Both GIT involvement and cachexia from 
chronic inflammation play a key role in malnutrition [51]. However, there are other 
additional risk factors for malnutrition worth mentioning, e.g. depression and 
anxiety, although their significance is uncertain [1, 84].
According to the data from the Canadian Scleroderma Research Group database 
on almost 600 SSc patients, malnutrition correlates with disease duration and 
severity, severity of anaemia, abdominal distension and the rate of subjective 
complains [51]. The American Society of Parenteral and Enteral Nutrition (ASPEN) 
recommends early screening for malnutrition in every patient with newly diag-
nosed SSc and then annually [85]. Screening is performed by examination of blood 
samples for chosen parameters: haemoglobin, iron and vitamin B12, serum levels 
of fat-soluble vitamins, prealbumin, albumin and additional test for micro- and 
macronutrient deficiency, particularly in suspected SIBO [86].
Patients at risk are indicated to rigorous monitoring and prompt treatment 
optimally in cooperation with dietitian and gastroenterologist [85]. At the advanced 
stage, nasoenteral feeding should be tried, eventually a percutaneous endoscopic gas-
trostomy or jejunostomy in case of severe gastroparesis. The last-mentioned approach 
carries the advantage of reduction of pulmonary aspiration risk. The most severe 
refractory intestinal involvement is indicated to parenteral nutrition (PN) [14].
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5. Alterations of body composition
Negative changes of bone mineral density (BMD), weight loss and muscle 
atrophy are associated with the nutrition insufficiency, but can also be related to 
reduced ability of physical activities, and severity of the disease. There are only 
few studies investigating alterations of body composition (BC) in SSc. Up to date, 
no large study or meta-analysis is available. Studies mostly used dual-energy X-ray 
absorptiometry, which is a suitable method for measuring BMD, lean body mass 
(LBM) and fat mass (FM) [87].
Studies have reported reduced BMD, which is determined by many factors: 
malnutrition and vitamin D deficiency, decreased physical activity, corticosteroid 
and immunosuppressive treatment and the disease-specific features [88, 89]. Low 
circulating levels of vitamin D may be related to the extent of skin involvement [90].
Studies on BC including body mass index (BMI) and other methods are scarce 
and their results differ. One study describes no alterations of FM or LBM in SSc 
patients compared to control population [90]. On the contrary, another study 
reported significantly lower BMI, LBM and FM as well as lower BMD in SSc women 
compared to healthy women, whereas more significant alterations of BC were 
expressed in dcSSc [91]. BMI significantly negatively correlated with duration of 
the disease in SSc patients, which was also the only risk factor associated with low 
LBM (sarcopenia). Of interest, reported negative changes of BC were not associated 
with current dietary customs [91].
One study reported decreased left ventricular mass (LVM) evaluated by 
echocardiography as a potential marker of malnutrition, whereas LVM correlated 
positively with BMI and severity of vascular involvement but negatively with skin 
thickening [92]. Another study reported the correlation of visceral abdominal 
fat with the main cardiovascular risk factors [93]. Both these studies are lacking a 
control group.
There is a strong need for large, well-designed studies including complex 
methods for evaluation of BC and disease-specific features and an adequate control 
group, so that the consequences of BC alterations could be properly elucidated and 
managed.
6. Diagnostic tools
Every patient diagnosed with SSc should be referred to a gastroenterologist, 
even if asymptomatic regarding GIT involvement [14]. Problematic swallowing and 
oral pathology should be examined by other specialists (dentists, speech patholo-
gists and eventually an oral surgeon) [1]. Social and psychosocial factors have 
certain impacts on some GIT symptoms and hence should be taken into consider-
ation too.
A wide spectrum of investigation methods is available for detection of GIT 
involvement, including laboratory and imaging methods [14]. Endoscopy has a key 
role in evaluation of oesophageal and gastric involvement and is used for therapeutic 
interventions as well. Except for video endoscopy, manometry and pH test are also 
useful in testing dysmotility and reflux (especially refractory GERD) [86, 94]. 
Barium oesophagogram is indicated for detection of suspect strictures [95]. Barrett’s 
oesophagus requires regular screening by endoscopic biopsies with frequency 
depending on the baseline finding: no initial dysplasia should be screened every 
3–5 years, and low-grade or high-grade dysplasia is recommended for control screen-
ing every 3–6 months. Endoscopy is also indicated in anaemia due to suspected 
GAVE [86]. Gastroparesis should be confirmed by RDG (delayed gastric emptying), 
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before administration of prokinetics [96]. Endoscopy in small intestinal involvement 
(e.g. capsule endoscopy) is restricted and difficult, particularly if dysmotility is the 
main symptom.
Diagnosis of SIBO is based on subjective complains and objective signs of 
malabsorption—weight loss and nutrient deficiency—confirmed by results of 
blood test showing low serum carotene level (marker of vitamin A absorption), low 
vitamin B12, 25-hydroxyvitamin D, iron, pathologic prothrombin time, etc. [86]. 
Though breath test has good specificity, the sensitivity is poor (65–70%) and is 
not able to detect bacterial overgrowth in more distal parts of the small intestine 
[97, 98]. Invention of appropriate diagnostic tools for evaluation of SIBO is still an 
unmet need.
7. Patient-reported outcomes
Validation and measurement of the consequences and outcomes related to 
certain disease and involvement can be challenging. Construction of appropri-
ate  questionnaires for evaluating SSc patients’ symptoms and correlating them to 
objective disease features was the task in the last decade [14]. The first questionnaire 
assessing the overall severity and quality of life in the context of GIT involvement was 
the Scleroderma Gastrointestinal Tract 1.0 (SSC-GIT 1.0), validated in 2009 [99]. 
Later it was revised, shortened and adapted into final version called University of 
California, Los Angeles Scleroderma Clinical Trial Consortium GIT 2.0 (UCLA SCTC 
GIT 2.0) [100]. This revised questionnaire consists of 33 items taken from SSC-GIT 
1.0 and 1 new item evaluating rectal incontinence (faecal soilage). Total GIT score 
correlates with the overall burden of GIT disease in SSc patients [100].
Another instrument developed by the National Institutes of Health is called 
Patient-Reported Outcome Measurement Information System (PROMIS) GI 
symptom item [101]. Compared to UCLA SCTC GIT 2.0, PROMIS contains more 
items and has additional scales for disrupted swallowing, nausea and vomiting. 
There is large correlation and satisfactory reliability between this two instruments, 
but PROMIS seems to be more easily comprehensible for general and low-literacy 
population, usable across diverse populations and less demanding for respondents 
to fulfil [102]. The only validated tool for evaluating the malnutrition in SSc 
patients is Malnutrition Universal Screening Tool (MUST) [103]. MUST is one of 
screening tools recommended by North American expert panel for initial screening 
of malnutrition in SSc patients, as it is easy to administer [85]. MUST reflects the 
weight change and acute dietary intake and can be less sensitive to nutritional status 
and GIT involvement than another tool Subject’s Global Assessment (SGA) [104]. 
Although MUST can identify the severity of malnutrition in SSs, it does not reflect 
the symptomatology contributing to this problem [105]. MUST is generally recom-
mended as the screening tool for nutritional status by several groups (European 
Society for Clinical Nutrition and Metabolism, ESPEN; National Institute for Health 
and Care Excellence, NICE; and North American expert panel [106].
8. Therapy
8.1 Current therapeutic options
To date, no specific disease-modifying drugs exist to stop the progress of the 
disease. Early diagnosis of SSc organ involvement is essential for symptomatic 
organ-specific treatment, until the irreversible fibrotic and hardly treatable damage 
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develops [14]. Currently, treatment of SSc-related gastrointestinal involvement is 
based on symptomatic therapy and includes acid-reducing therapy and administra-
tion of antibiotics and prokinetics. Octreotide is prescribed in refractory small 




Initial therapy/examination Other therapeutic approaches and 
lifestyle modifications
GERD Modification of diet and lifestyle
PPI (daily administration)
1) Take PPI at least 30 minutes prior to 
eating; control the right intake
2) Consider increasing the dose of PPI—
twice a day—or change the PPI drug
3) Add an H2 blocker at night
4) If symptoms are still present, perform 
pH-metry or endoscopy
Lifestyle and diet modification:
Small meals more frequently during the 
day, more food in the first half of the day; 
take a walk after eating; restrict from 
aggravating foods; sleep with the upper 




Optimal therapy of GERD, 
monitoring by a gastroenterologist, 
regular upper endoscopy
Radiofrequency ablation (RFA)—
consider in low- or moderate-grade 
dysplasia, always indicated in high-grade 
dysplasia
Stricture Optimal therapy of GERD Consider endoscopic dilation, in case of 
persistent dysplasia
Gastroparesis Prokinetics (after gastric emptying 
study to confirm delayed gastric 
emptying)
1) Modification of diet (small meals, 
walking after meal), adequate liquid intake
2) Metoclopramide (ECG monitoring due to 
risk of prolonged QT interval)
3) Domperidone or erythromycin (if QT 
interval is normal)
4) Treatment of nausea
GAVE Firstly, upper endoscopy to verify 
the diagnosis; argon plasma therapy 
in case of active bleeding; support 
therapy in case of bleeding (red blood 
cell transfusion, etc.)
1) Repeated sessions of argon plasma 
therapy
2) Laser therapy as an alternative approach
3) Immunosuppressive therapy in indicated 
cases
SIBO Breath test (poor sensitivity)
Examination of malabsorption 
(laboratory tests, body composition)
Therapeutic trial with antibiotics 
(metronidazole, ciprofloxacin, 
neomycin, rifaximin, amoxicillin, 
doxycycline)
1) Administration of antibiotics for 
2 weeks—in recurrent cases repeat cyclic 
antibiotics therapy
2) Probiotics






Imaging examination to exclude the 
mechanical cause of obstruction 
(X-ray, CT)
Initial therapy and nutritional 
support during the hospitalisation
1) Nutritional support
2) Prokinetics (subcutaneous octreotide)
3) Broad-spectrum antibiotics
4) Surgery (in resistant cases, to provide 
decompression)
Malnutrition Regular screening, BMI examination, 
recommended screening tools 
(MUST)
Laboratory markers of malnutrition
1) Nutritional support
2) (Total) parenteral nutrition
3) Percutaneous feeding tubes (endoscopy 
gastrostomy)
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Firstly, non-pharmacological treatment—lifestyle modification—should be 
applied to improve symptoms: elevation of the head or upper half of the body in 
the bed, sleeping on the left side, modification of eating regimen (indigestion of 
multiple small meals during the day, avoidance of eating meal less than 3 or 4 hours 
before bedtime), loss of weight if obesity, cessation of smoking and minimalizing 
alcohol intake, avoidance of drinking beverages and taking food or drugs decreasing 
the LES pressure (caffeine drinks, chocolate, calcium channel blockers, nitrates) 
and appropriate education about using risk drugs (bisphosphonates, tetracycline, 
iron, NSAIDs) [86].
The last update of EULAR recommendations published in 2017 has summarised 
the up-to-date treatment management into three points: (1) PPI for treatment 
of SSc-related GERD and prevention of oesophageal ulcers, strictures and other 
adverse consequences, (2) prokinetics for control of the GIT dysmotility and 
(3) intermittent or rotating cycles of antibiotics for treatment of symptomatic 
SIBO. However, large randomised control trial (RCT) studies evaluating the above-
mentioned medication in SSc are lacking [108].
A small RCT reported favourable effect of PPI on improvement of upper GIT 
symptoms in SSc [109]. Moreover, omeprazole potentially reduces or regresses the 
oesophageal fibrosis [110, 111]. On the other hand, long-term therapy with PPI 
potentially decreases the intestinal absorption and thus causes nutritional defi-
ciency. It is associated with the risk of bacterial overgrowth and infections  
(C. difficile) and more adverse effects (cardiovascular disease, malignancy, demen-
tia, etc.) [112]. H2 receptor antagonists (H2RA) are prescribed as the next step in 
GERD treatment, either in monotherapy or in combination with PPI [113]. H2RA 
control mainly the nocturnal histamine-dependent acid secretion, which is refrac-
tory to PPI [86].
Treatment by prokinetics is based on individual symptoms of GIT dysmotility 
and potential benefit to risk [108]. Several non-randomised or uncontrolled studies 
reported improvement of GI symptoms in SSc [107, 114–116]. Prokinetics improve 
refractory GERD symptoms via supporting the gastric emptying in cases of gastro-
paresis in patients treated adequately for GERD. Combination with antiemetics is 




Initial therapy/examination Other therapeutic approaches and 
lifestyle modifications
Constipation “Bowel hygiene” (adequate liquid and 
fibre intake), defaecation in timely 
manner, taking regular exercise or 
other physical activity
Osmotic laxatives, stool softeners
Diarrhoea Firstly, identify the cause of diarrhoea 
(other than SSc or multifactorial)
Management of the cause of diarrhoea 
(dysmotility, SIBO, fat malabsorption, etc.)
Faecal 
incontinence
Management of diarrhoea and SIBO, 
biofeedback, pelvic-floor exercises
Sacral nerve stimulation in resistant cases
*FODMAP foods: inappropriate and irritating ingredients in patients with irritable bowel syndrome or chronic 
bowel disease (idiopathic bowel inflammation, celiac disease, etc.); FODMAP diet consists of eliminating the intake 
of these foods: fermentable oligosaccharides (gluten, onion, garlic, etc.), disaccharides (lactose), monosaccharides 
(fructose) and polyols (alcohol sugars)—these are poorly absorbable carbohydrates in the small intestine.
Adapted from Ref. [86]; Abbreviations: GIT, gastrointestinal tract; GERD, gastro-oesophageal reflux disease; 
PPIs, proton-pump inhibitors; ECG, electrocardiogram; GAVE, gastric antral vascular ectasia, SIBO, small 
intestinal bacterial overgrowth; CT, computed tomography; BMI, body mass index; MUST, Malnutrition Universal 
Screening Tool
Table 1. 
Therapeutic intervention and follow-up of SSc patients with GIT involvement
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in the early disease stage. Nevertheless, there is only a little or no profit from using 
prokinetics in later stages with dominant smooth muscle atrophy [96]. Choice of a 
certain drug from this group depends on individual benefit for each patient [86]. 
Small studies in patients with SSc and other connective tissue diseases reported 
a beneficial effect of cisapride [117–121]. However, cisapride can cause long QT 
syndrome predisposing to severe arrhythmias; thus it is not commonly available 
in some countries [122]. Metoclopramide is the first-line therapy in gastroparesis, 
followed by domperidone, erythromycin, or eventually pyridostigmine. Using these 
medicaments also requires monitoring for adverse effects [86].
In patients suspected for SIBO, intermittent or rotating administration of 
antibiotics is indicated. The current approach is based on empirical courses of one 
or more broad-spectrum antibiotics [123]. A therapeutic trial is performed for 
2 weeks, without any testing. After these courses of antibiotics, gastrointestinal 
symptoms are assessed and if there is no improvement, cyclical courses of anti-
biotics continue every 2 weeks altered by 2 weeks off [86]. Therapy duration and 
regimen depend on the severity and recurrence of symptoms and clinical response 
[86]. Two small studies reported favourable effect of antibiotics in SSc-related SIBO 
[61, 124]. Nutritional status should not be omitted, and the supplementation should 
be eventually started at the same time as antibiotics [86]. Probiotics have favourable 
effect on symptoms and are suitable also in combination with antibiotics [125, 126].
There are more aspects of GIT involvement treatment. Regarding GERD, some 
studies reported favourable effect of GABA-B (gamma-aminobutyric acid receptor 
type B) agonists or metabotropic glutamate receptor antagonists (mGluR), which 
slow the decrease of basal LES pressure [127]. However, the beneficial effect has 
yet to be studied in SSc [86]. New pharmacological targets are still investigated, 
e.g. nitrous oxide synthase, cannabinoid, muscarinic or opioid receptors, etc., 
which reduce the transient LES relaxation. Surgical intervention is not generally 
recommended in SSc, because of association with increased risk of complications 
compared to general population, especially worsening of dysphagia [86].
Interventional endoscopy is the method of choice in indicated patients, e.g. 
endoscopic dilation of confirmed strictures should not be performed empirically 
due to the risk of perforation [128–130]. Laser or argon plasma coagulation is 
performed in GAVE, after adequate supplementation therapy of anaemia. Surgery 
should be the last solution after all strategies fail [86, 131].
Intestinal pseudo-obstruction requires exclusion of mechanical obstruction 
(RDG or computer tomography). Basal therapeutic approach lies in bowel rest, 
nutritional support, correcting electrolyte imbalance and use of prokinetics 
and antibiotics for coexisting SIBO [86]. In most cases (70%), this conservative 
treatment leads to spontaneous resolution. Some patients are indicated for sur-
gery (9%) [132]. Subcutaneous octreotide at doses 50–200 micrograms per day is 
also recommended [86].
Treatment of large bowel symptoms is mainly symptomatic, including dietary 
measure and administration of laxatives or antidiarrhoeal drugs according to the 
dominant symptomatology [86]. Before the treatment of constipation, obstruction 
has to be excluded and current medication should be revised to avoid constipating 
drugs [133]. Aetiology of diarrhoea should be evaluated to exclude other aetiology, e.g. 
infections or other autoimmune disorders (celiac disease, microscopic colitis, amy-
loidosis). Antidiarrhoeal drugs (loperamide) have to be used with caution, because 
of the risk of pseudo-obstruction [86]. Bile acid sequestrants can be used to improve 
fat malabsorption in case of SIBO [133]. Incontinence is difficult to treat and requires 
complex approach consisting of management of diarrhoea, behavioural therapy 
(anorectal biofeedback), pelvic-floor exercise and eventually neuronal stimulation of 
sacral nerve—a microsurgery intervention [86].
New Insights into Systemic Sclerosis
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8.2 Therapy of malnutrition
Enteral and sometimes long-term parenteral nutrition is often needed in pro-
gressive and advanced disease [1]. There are no studies available on enteral nutrition 
in SSc patients [83]. The North American expert panel recommends dietary supple-
mentation in similar manner to treatment in patients with chronic diseases. In case 
of gastroparesis, dietary measures are recommended (low-fibre, low-fat, frequent 
small meals and higher content of liquid) along with regular monthly monitoring 
of body weight [83]. Alternative ways of enteral nutrition in case of insufficient oral 
alimentation are gastric or jejunal feeding [1]: percutaneous endoscopic gastros-
tomy (PEG) tube feeding, nasojejunal tube, or percutaneous or surgically placed 
enteral tube feeding in case of refractory gastroparesis and preserved normal small 
bowel function, or by PN [134, 135].
PN is an emerging option of treatment for patients with refractory malnutri-
tion, where the EN is not sufficient (e.g. SIBO) or where surgical enteral nutrition 
may be difficult to provide (severe cutaneous fibrosis and thickening) [1]. The 
main disadvantages of PN are in general the cost and PN-related complications: 
catheter-related bloodstream infections; liver function abnormalities (e.g. cholesta-
sis); metabolic bone disease; fluid overload, especially in patients with ILD and 
pulmonary arterial hypertension; electrolyte imbalances; and risk of central vein 
thrombosis in predisposed patients [136–140]. Moreover, specific problems with 
PN in SSc are caused by skin involvement, poor quality of veins due to vasculopathy 
and hand deformities requiring assistance with PN infusion [1].
Data on long-term PN in SSc patients are lacking. However, based on studies on 
PN in patients with chronic intestinal pathology and the data from retrospective 
studies on PN nutrition in SSc patients, which reported the improvement of quality 
of life and patients’ profit from this therapy, this therapeutic approach is considered 
as effective in SSc patients [136, 141–144]. Regular monitoring for complications, 
control of body weight and adequate altering of nutrient supplements are recom-
mended, along with the establishment of a team for patients’ education, prevention 
of the catheter-related complications and optimising the nutrition intake. The 
optimal duration of PN needs to be determined [1].
8.3 Future therapeutic prospects
Novel therapeutic options of SSc GIT involvement are investigated, particularly 
immunosuppressive drugs targeting pro-fibrotic cytokines and IVIGs. Effect of 
IVIG therapy is multiple: anti-idiotypic-mediated neutralisation of muscarinic, 
anti-fibroblast or anti-endothelial cell circulating autoantibodies and reduction of 
pro-fibrotic cytokines. IVIG has a better safety profile compared to immunosup-
pressive drugs [14]. Observational studies confirmed its potential to improve GIT 
symptoms and reverse cholinergic dysfunction induced by M3-R autoantibodies 
in vivo [145–147]. Another therapeutic approach is targeting miRNA-29 by anti-
miRNA chemically modified oligonucleotides [148]. However, future large-scale 
controlled studies are needed to confirm the beneficial effects of these promising 
approaches in SSc patients.
9. Conclusion
Gastrointestinal involvement is highly prevalent in systemic sclerosis, affects the 
majority of patients and can be hidden or can precede the obvious skin manifesta-
tion. Therefore, overall screening is recommended for early management of the 
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gastrointestinal involvement until the ultimate damage develops. The pathophysiol-
ogy and specific therapy are still the focus of research, with some promising pros-
pects. To date, the cornerstone of the treatment is mainly symptomatic therapy and 
adequate nutritional support, best managed in cooperation with other specialists. 
The general impact of this involvement on patients’ health status and quality of life 
should not be omitted. Large studies are required to examine aetiopathology and 
treatment options, including new therapeutic agents, and also complex impact of 
gastrointestinal involvement on patients’ status (Table 2).
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Identify pathoorganisms triggering the 
disease (e.g. Helicobacter pylori [9])
Identify the insult/toxin triggering the disease 





Association of well-known autoantibodies 
with the disease features and their role in 
pathogenesis (anti-topoisomerase I, anti-
polymerase III, etc.)
Identify new autoantibodies and their role in 
pathogenesis (e.g. IgG antibodies binding the 
M3 receptor for acetylcholine)




Onset of the disease
Extent and severity of 
involvement
Progression




Identify the factors/disease characteristics 
increasing the risk of malignancy
Determine the risk compared to general 





Prevalence and character 
of negative changes of 
body composition
Composition of a sensitive and specific tool 
for evaluation of nutrition and complications 
leading to malnutrition (e.g. SIBO)
Recommendation of an appropriate tool 
for examination of body composition and 
frequency of such testing
Therapy Future specific therapy, 
targeted at specific 
mechanisms (molecules, 
antibodies, etc.) 
implicated in pathogenesis 
of the disease
IVIG (evidence of anti-idiotypic-mediated 
neutralisation of muscarinic, anti-fibroblast 
or anti-endothelial cell circulating 
autoantibodies and reduction of pro-fibrotic 
cytokines)
Targeting RNA with small molecules; anti-





Brief list of unmet needs and tasks for future research
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